Volume | 668 |
|
|||||
News | - | ||||||
Day High | 6.2239 | Low High |
|||||
Day Low | 5.73 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
CollPlant Biotechnologies Ltd | CLGN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.97 | 5.73 | 6.2239 | 5.979 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10 | 668 | US$ 5.97 | US$ 3,989 | - | 4.22 - 8.90 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
10:19:44 | 271 | US$ 6.2239 | USD |
CollPlant Biotechnologies Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
64.12M | 11.19M | - | 10.96M | -7.02M | -0.63 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CollPlant Biotechnologies News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLGN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.39 | 6.40 | 5.5101 | 6.17 | 5,445 | -0.1661 | -2.60% |
1 Month | 5.35 | 6.75 | 5.31 | 6.14 | 5,586 | 0.8739 | 16.33% |
3 Months | 5.40 | 6.75 | 4.22 | 5.41 | 6,482 | 0.8239 | 15.26% |
6 Months | 5.80 | 6.99 | 4.22 | 5.50 | 10,455 | 0.4239 | 7.31% |
1 Year | 7.15 | 8.90 | 4.22 | 6.14 | 12,388 | -0.9261 | -12.95% |
3 Years | 14.94 | 23.49 | 4.22 | 12.35 | 26,273 | -8.72 | -58.34% |
5 Years | 5.10 | 24.26 | 3.3499 | 12.65 | 28,281 | 1.12 | 22.04% |
CollPlant Biotechnologies Description
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. |